Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome
ConclusionThe use ofSaccharomyces cerevisiae CNCM I-3856 in IBS at a dose of 2 billion CFU twice daily for 8 weeks has shown to have an improvement in abdominal pain and stool consistency due to its analgesic and anti-inflammatory activity in subjects with IBS.
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research
More News: Gastroenterology | Health Management | Irritable Bowel Syndrome | Pain | Statistics | Study